Targeted genome editing in acute lymphoblastic leukemia: A review

Citations of this article
Mendeley users who have this article in their library.

This article is free to access.


Background: Genome editing technologies offers new opportunities for tackling diseases such as acute lymphoblastic leukemia (ALL) that have been beyond the reach of previous therapies. Results: We show how the recent availability of genome-editing tools such as CRISPR-Cas9 are an important means of advancing functional studies of ALL through the incorporation, elimination and modification of somatic mutations and fusion genes in cell lines and mouse models. These tools not only broaden the understanding of the involvement of various genetic alterations in the pathogenesis of the disease but also identify new therapeutic targets for future clinical trials. Conclusions: New approaches including CRISPR-Cas9 are crucial for functional studies of genetic aberrations driving cancer progression, and that may be responsible for treatment resistance and relapses. By using this approach, diseases can be more faithfully reproduced and new therapeutic targets and approaches found.




Montaño, A., Forero-Castro, M., Hernández-Rivas, J. M., García-Tuñón, I., & Benito, R. (2018, July 17). Targeted genome editing in acute lymphoblastic leukemia: A review. BMC Biotechnology. BioMed Central Ltd.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free